Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 6Phase 2/3 4Phase 1/2 1Phase 1 1

Status

Completed 25Unknown 6Terminated 3

Sponsor Class

OTHER 2INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 3Invasive Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2 Positive Metastatic Breast Cancer 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Lapatinib × Clear all
NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
240 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Bio-Thera Solutions

Phase 3 Unknown
410 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT01104571 2018-09-17

EPHOS-B

Institute of Cancer Research, United Kingdom

Phase 3 Unknown
257 enrolled
Breast

Breast Neoplasms

NCT02394496 2016-06-15

OVER

Consorzio Oncotech

Phase 3 Unknown
396 enrolled
Breast

Breast Neoplasms

NCT00486668 2016-06-06

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

NSABP Foundation Inc

Phase 3 Unknown
529 enrolled
Breast

Invasive Breast Cancer

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

National Cancer Institute (NCI)

Phase 3 Unknown
396 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡